홈 › 급성 골수성 백혈병 › 오하이오 › Columbus
OH Columbus의 급성 골수성 백혈병 임상 시험
급성 골수성 백혈병 관련 연구 35개가 Columbus 및 인근(약 30마일 이내) 지역에서 참여자를 모집하고 있습니다. 연구 항목을 열어 참여 자격 및 연구 팀 연락처를 확인하세요.
공식 연구 텍스트(영어)
연구 대상자를 모집 중이신가요? 이 페이지 상단에 노출하세요 — 30일 동안 $99 →
Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
피험자 모집 중2상
- Ohio State University Comprehensive Cancer Center, Columbus
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
피험자 모집 중관찰 연구건강한 지원자 환영
- Ohio State University Comprehensive Cancer Center, Columbus
- Mount Carmel East Hospital, Columbus
- The Mark H Zangmeister Center, Columbus
- 외 8개
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
피험자 모집 중2상
- Ohio State University Comprehensive Cancer Center, Columbus
Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
피험자 모집 중1상
- Ohio State University Comprehensive Cancer Center, Columbus
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
피험자 모집 중2상
- Ohio State University Comprehensive Cancer Center, Columbus
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
피험자 모집 중2상
- Ohio State University Comprehensive Cancer Center, Columbus
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
피험자 모집 중3상
- Nationwide Children's Hospital, Columbus
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
피험자 모집 중1/2상
- Ohio State University, Columbus
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
피험자 모집 중1상
- Ohio State University, The James Comprehensive Cancer, Columbus
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
피험자 모집 중1/2상
- The Ohio Sate University, Columbus
Vyxeos for Re-induction Treatment of Acute Myeloid Leukemia Patients With Persistent Disease After Induction
피험자 모집 중1/2상
- Ohio State University Comprehensive Cancer Center, Columbus
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
피험자 모집 중관찰 연구
- OhioHealth Research Institute, Columbus
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
피험자 모집 중3상
- US-Colombus OH-OSU, Columbus
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
피험자 모집 중3상
- US-Colombus OH-OSU, Columbus
Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy
피험자 모집 중2상
- Ohio State University Comprehensive Cancer Center, Columbus
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
피험자 모집 중1상
- Ohio State University, Columbus
A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
피험자 모집 중1상
- Ohio State University Comprehensive Cancer Center, Columbus
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
피험자 모집 중1/2상
- Nationwide Children's Hospital, Columbus
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
피험자 모집 중3상
- Nationwide Children's Hospital, Columbus
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
피험자 모집 중3상
- Ohio State University, Columbus
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
피험자 모집 중관찰 연구
- Nationwide Children's Hospital, Columbus
- The Arthur G. James Cancer Hospital/The Ohio State University Medical Center, Columbus
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
피험자 모집 중2상
- Ohio State University Comprehensive Cancer Center, Columbus
Ivosidenib as Post-HSCT Maintenance for AML
피험자 모집 중2상
- Ohio State University Wexner Medical Center- James Cancer Hospital, Columbus
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
피험자 모집 중1상
- Ohio State University Comprehensive Cancer Center, Columbus
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
피험자 모집 중1상
- The Ohio State University, Columbus
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
피험자 모집 중2/3상
- Ohio State University Comprehensive Cancer Center (OSUCCC) - The James Cancer Hospital and Solove Research Institute, Columbus
Expanded/Activated Gamma Delta T-cell Infusion Following Hematopoietic Stem Cell Transplantation and Post-transplant Cyclophosphamide
피험자 모집 중1상
- Ohio State University Medical Center, Columbus
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
피험자 모집 중1/2상
- The Ohio State University Comprehensive Cancer Center, Columbus
Ziftomenib Maintenance Post Allo-HCT
피험자 모집 중1상
- Ohio State University Wexner Medical Center- James Cancer Hospital, Columbus
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
피험자 모집 중1상
- The James Cancer Hospital and Solove Research Institute, Columbus
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
피험자 모집 중1상
- The Ohio State University Wexner Medical Center - James Cancer Hosp, Columbus
HPC Offered for PRESERVE Expansion
피험자 모집 중관찰 연구
- The Ohio State University Medical Center, Columbus
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
피험자 모집 중1/2상
- The Ohio State University Wexner Medical Center, Columbus
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
피험자 모집 중건강한 지원자 환영
- Ohio State University, Columbus
Safety and Efficacy of Expanded, Universal Donor Natural Killer Cells for Relapsed/Refractory AML
피험자 모집 중1/2상
- Nationwide Children's Hospital, Columbus
다른 도시의 급성 골수성 백혈병 시험
- Houston, TX연구 85개
- New York City, NY연구 51개
- Boston, MA연구 44개
- Baldwin Park, CA연구 40개
- Seattle, WA연구 40개
- Philadelphia, PA연구 34개
- Durham, NC연구 33개
- Atlanta, GA연구 30개
- Tampa, FL연구 29개
- Chicago, IL연구 26개
- Portland, OR연구 25개
- Miami, FL연구 24개
Columbus의 다른 연구
- 비소세포폐암연구 56개
- 유방암연구 39개
- 난소암연구 39개
- 암 (전체)연구 38개
- 폐암연구 37개
- 만성 림프구성 백혈병연구 28개
- 전이성 암연구 27개
- 자궁내막암연구 25개
- 대장직장암연구 24개
- 전립선암연구 24개
- 다발성 골수종연구 24개
- 흑색종연구 21개
ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.